ANVS:NYE-Annovis Bio, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 4.78

Change

-0.18 (-3.63)%

Market Cap

USD 0.03B

Volume

0.03M

Average Target Price

USD 12.00 (+151.05%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.07 (+0.10%)

USD160.13B 24.87 2.76
ADPT Adaptive Biotechnologies Corpo..

+0.95 (+2.02%)

USD6.19B 38.68 N/A
BHVN Biohaven Pharmaceutical Holdin..

+2.34 (+3.92%)

USD3.56B N/A N/A
ADCT ADC Therapeutics SA

-9.34 (-20.64%)

USD3.22B -99,999.99 N/A
MYOV Myovant Sciences Ltd

+0.26 (+1.16%)

USD2.01B N/A N/A
ZYME Zymeworks Inc

+0.13 (+0.30%)

USD2.00B 300.20 N/A
RCUS Arcus Biosciences, Inc

-0.46 (-2.40%)

USD1.23B N/A N/A
KDMN Kadmon Holdings, Inc

-0.04 (-0.93%)

USD0.73B 2.20 N/A
CVM CEL-SCI Corporation

-0.05 (-0.37%)

USD0.52B N/A N/A
PFNX Pfenex Inc

+0.18 (+1.42%)

USD0.43B 268.67 63.90

ETFs Containing ANVS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 73,438.46% 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 73,438.46% 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain 4,926.25% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 4,926.25% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11,588.13% N/A N/A N/A N/A
Risk Adjusted Return 42.51% N/A N/A N/A N/A
Market Capitalization 0.03B 16% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 83% B 99% A+
Price/Book Ratio 3.72 60% D- 22% F
Price / Cash Flow Ratio -71.47 94% A 97% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -75.85% 60% D- 6% F
Return on Invested Capital 11.11% 90% A- 75% C
Return on Assets -50.46% 32% F 1% F
Debt to Equity Ratio -5.83% 63% D 95% A
Technical Ratios  
Short Ratio 0.29 94% A 85% B
Short Percent 0.32% 97% A+ 90% A-
Beta -0.53 93% A 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector